))
Dermatology Edition: Top Headlines for Week of October 16, 2023
Manage episode 407442253 series 3560281
Contenido proporcionado por Healio. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Healio o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
In this edition, FDA issues complete response letter for relabotulinumtoxinA; mucocutaneous manifestations may signal COVID-induced inflammatory disease in children and more. Read the full coverage here:
FDA issues complete response letter for relabotulinumtoxinA for frown lines, crow’s feet
Mucocutaneous manifestations may signal COVID-induced inflammatory disease in children
FDA approves Zoryve for pediatric psoriasis
Colloidal oatmeal, prescription cream comparable in Black children with atopic dermatitis
FDA issues complete response letter for lebrikizumab for eczema treatment
References:
Imam B. Mucocutaneous clinical manifestation of multi-system inflammatory syndrome in children (MIS-C). Presented at: Skin of Color Update; Oct. 6-8, 2023; New York.
Lisante TA, et al. J Dermatolog Treat. 2023;doi:10.1080/09546634.2023.2241587.
121 episodios
Compartir
